Torrent Pharmaceuticals Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

Torrent Pharmaceuticals announced that the USFDA inspected its Dahej manufacturing unit from 19 January 2026 to 23 January 2026. The inspection concluded with Zero observations.

Powered by Capital Market - Live News

Torrent Pharmaceuticals Ltd is up for a third straight session in a row. The stock is quoting at Rs 4088, up 1.74% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.67% on the day, quoting at 25522.15. The Sensex is at 83010.66, down 0.67%. Torrent Pharmaceuticals Ltd has added around 7.13% in last one month.

Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has added around 3.29% in last one month and is currently quoting at 22217.05, down 0.2% on the day. The volume in the stock stood at 2.43 lakh shares today, compared to the daily average of 2.11 lakh shares in last one month.

The benchmark January futures contract for the stock is quoting at Rs 4087.1, up 1.65% on the day. Torrent Pharmaceuticals Ltd is up 29.19% in last one year as compared to a 9.33% gain in NIFTY and a 0.04% gain in the Nifty Pharma index.

The PE of the stock is 63.73 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

Torrent Pharma has approved the issuance of Secured, Rated, Listed, Redeemable Non-Convertible Debentures (NCDs) aggregating upto Rs 12,500 crore in one or more tranches on private placement basis.

Powered by Capital Market - Live News

Torrent Pharmaceuticals said India Ratings and Research has reaffirmed the credit rating of the company?s existing banking facilities, issuer rating and non-convertible debentures at IND AA+ with a stable outlook.

The rating agency has also assigned a short-term rating of IND A1+ to Torrent Pharma's proposed commercial paper programme, indicating a strong degree of safety with respect to timely servicing of financial obligations.

The company's securities transfer and stakeholders relationship committee will meet on 5 January 2026 to consider the issuance of secured non-convertible debentures through a private placement, within the borrowing limits already approved by the board in July 2025.

Torrent Pharma is the flagship company of the Torrent Group. It is ranked 7th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology. It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved.

On a consolidated basis, the company's net profit rose 30.46% to Rs 591 crore while net sales rose 14.66% to Rs 3246 crore in Q2 September 2025 over Q2 September 2024.

Shares of Torrent Pharmaceuticals rose 0.96% to settle at Rs 3884.85 on Friday, 2 January 2026.

Powered by Capital Market - Live News